<DOC>
	<DOCNO>NCT00138697</DOCNO>
	<brief_summary>The kinetics , efficacy safety liquid intravenous immunoglobulin product , IVIG-L , study patient hypogammaglobulinemia , regularly treat intravenous immunoglobulin substitution therapy .</brief_summary>
	<brief_title>Kinetics , Efficacy Safety IVIG-L Hypogammaglobulinemia Patients</brief_title>
	<detailed_description>Sanquin develop , cooperation Finnish Red Cross Blood Transfusion Service ( FRCBTS ) , liquid intravenous immunoglobulin product , IVIG-L . The liquid formulation intravenous immunoglobulin simplifies infusion , eliminate possible mistake reconstitution water injection reduce space requirement storage . In addition donor selection donor screening , several viral safety step include production process . In clinical trial , efficacy safety IVIG-L patient hypogammaglobulinemia , regularly treat intravenous immunoglobulin substitution therapy , study . IVIG-L also study patient chronic ITP ( KB98001 ) . Data study use application marketing authorisation Finland Netherlands .</detailed_description>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Primary hypogammaglobulinemia , particularly patient Xlinked agammaglobulinemia ( XLA ) Common Variable Immunodeficiency ( CVID ) Used replacement treatment intravenous immunoglobulin 24 week interval A stable clinical situation ( activity disease ; stable immunoglobulin dose ) Age &gt; 18 year The patient/legally acceptable representative sign consent form Treatment investigational drug within 7 day study entry previous enrolment study Known allergic reaction human plasma plasma product Have ongoing progressive terminal disease , include HIV infection Pregnancy lactation Known insufficiency coronary cerebral circulation Have renal insufficiency ( plasma creatinine &gt; 115Âµmol/L ) Have ongoing active disease cause general symptom , e.g . chronic active hepatitis , persistent enterovirus infection . Have IgA deficiency , antiIgA antibody detect Active systemic lupus erythematosus ( SLE )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Agammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Immunoglobulins , Intravenous</keyword>
</DOC>